AXSM Axsome Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

AXSM [NASD]

Axsome Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.55	Insider Own	0.30%	Shs Outstand	37.06M	Perf Week	2.56%
Market Cap	3.19B	Forward P/E	-	EPS next Y	-2.90	Insider Trans	1.25%	Shs Float	28.84M	Perf Month	5.88%
Income	-90.20M	PEG	-	EPS next Q	-0.62	Inst Own	61.40%	Short Float	12.29%	Perf Quarter	47.89%
Sales	-	P/S	-	EPS this Y	-74.40%	Inst Trans	0.55%	Short Ratio	4.73	Perf Half Y	-4.81%
Book/sh	4.21	P/B	19.72	EPS next Y	-6.60%	ROA	-69.70%	Target Price	-	Perf Year	222.36%
Cash/sh	5.14	P/C	16.17	EPS next 5Y	-	ROE	-98.60%	52W Range	13.64 - 109.94	Perf YTD	-19.66%
Dividend	-	P/FCF	-	EPS past 5Y	-42.80%	ROI	-	52W High	-24.47%	Beta	3.14
Dividend %	-	Quick Ratio	7.60	Sales past 5Y	-	Gross Margin	-	52W Low	508.80%	ATR	5.03
Employees	45	Current Ratio	7.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.18	Volatility	5.03% 6.24%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	-172.30%	Profit Margin	-	Rel Volume	0.41	Prev Close	81.92
Shortable	Yes	LT Debt/Eq	0.10	Earnings	May 08 BMO	Payout	-	Avg Volume	749.79K	Price	83.04
Recom	1.40	SMA20	5.10%	SMA50	1.40%	SMA200	26.74%	Volume	304,140	Change	1.37%

Apr-28-20

Reiterated

H.C. Wainwright

Buy

$200 → $210

Apr-14-20

Initiated

Cowen

Outperform

$95

Dec-30-19

Reiterated

H.C. Wainwright

Buy

$170 → $200

Dec-17-19

Reiterated

H.C. Wainwright

Buy

$30 → $170

Dec-16-19

Reiterated

Guggenheim

Buy

$65 → $158

Oct-16-19

Initiated

Guggenheim

Buy

$48

Sep-18-19

Initiated

William Blair

Outperform

May-28-19

Initiated

SunTrust

Buy

May-23-19

Reiterated

H.C. Wainwright

Buy

$23 → $30

Apr-08-19

Initiated

SVB Leerink

Outperform

$25

Mar-15-19

Reiterated

H.C. Wainwright

Buy

$15 → $18

Oct-03-16

Resumed

Brean Capital

Buy

Dec-15-15

Initiated

Cantor Fitzgerald

Buy

Dec-14-15

Initiated

Ladenburg Thalmann

Buy

Jul-08-20 02:41PM	Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020 Motley Fool
Jul-07-20 11:14AM	3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap TipRanks
Jul-03-20 03:19PM	What Kind Of Investors Own Most Of Axsome Therapeutics, Inc. (NASDAQ:AXSM)? Simply Wall St.
Jun-29-20 12:49PM	Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation Zacks -10.99%
Jun-26-20 07:00AM	Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimers Disease Agitation GlobeNewswire +11.98%
Jun-15-20 12:24PM	Axsome Therapeutics, Inc. (AXSM): Are Hedge Funds Done Buying? Insider Monkey
Jun-07-20 11:30AM	Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report? Zacks
Jun-04-20 06:27PM	Edited Transcript of AXSM earnings conference call or presentation 8-May-20 12:00pm GMT Thomson Reuters StreetEvents
07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-29-20 01:38PM	Top Small Cap Stocks for June 2020 Investopedia
07:00AM	Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-26-20 12:57PM	Is Axsome Therapeutics a Buy? Motley Fool -5.23%
07:00AM	Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually GlobeNewswire
May-23-20 07:36AM	Better Buy: Biogen vs. Axsome Therapeutics Motley Fool
May-19-20 06:04AM	What's Behind Axsome Therapeutics' Miracle Pipeline? Motley Fool
May-11-20 11:56AM	Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses Zacks
May-09-20 02:00PM	Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript Motley Fool
08:10AM	Why Jazz Pharmaceuticals' Symphony of Growth Is About to End Motley Fool
06:47AM	Is Axsome Therapeutics a Screaming Buy? Motley Fool
May-08-20 07:00AM	Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-03-20 03:39PM	Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April Motley Fool
Apr-30-20 08:00AM	There May Be a New First-Line Treatment for Depression Motley Fool
07:00AM	Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020 GlobeNewswire
Apr-28-20 11:16AM	Axsome Shares Jump 25% on Alzheimer's Study Results GuruFocus.com
Apr-27-20 06:00AM	Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimers Disease Agitation GlobeNewswire +24.35%
Apr-07-20 12:37PM	Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study Zacks -6.87%
Apr-06-20 06:00AM	Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine GlobeNewswire
Apr-01-20 01:23PM	Edited Transcript of AXSM earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents -5.17%
Mar-31-20 05:05PM	Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study Zacks
04:52PM	5 Guru Stocks That Beat the Market GuruFocus.com
Mar-30-20 06:00AM	Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications GlobeNewswire -8.99%
Mar-29-20 08:53AM	Who Has Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares? Simply Wall St.
Mar-28-20 09:23PM	Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey
Mar-23-20 12:17PM	Axsome Expedites Completion Timeline of AD Study on AXS-05 Zacks +17.48%
09:50AM	Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock? Zacks
Mar-20-20 07:00AM	Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire +17.06%
Mar-12-20 07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -12.04%
Mar-05-20 07:00AM	Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer GlobeNewswire
Mar-04-20 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 GlobeNewswire +5.40%
Mar-02-20 10:33AM	What's in Store for Axsome (AXSM) This Earnings Season? Zacks +13.94%
Feb-20-20 07:00AM	Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine GlobeNewswire
Feb-19-20 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-28-20 06:32PM	Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know Zacks
Jan-23-20 09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
Jan-22-20 07:00AM	Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-13-20 06:00AM	Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizers Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate GlobeNewswire
Jan-09-20 02:50PM	Top Biotech Stocks for Q1 2020 Investopedia
Jan-03-20 10:44AM	3 Top Drug Stocks to Own In 2020 InvestorPlace -6.53%
08:56AM	Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? Zacks
Jan-02-20 07:57AM	The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine Zacks
Dec-31-19 09:26AM	Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study Zacks
08:42AM	Top 2019 Wall Street Stories That May Hit Headlines in 2020 Zacks
Dec-30-19 06:15AM	Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response GlobeNewswire
Dec-27-19 02:19PM	Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks
Dec-24-19 12:15PM	Biotech Leading in Q4: Best ETFs & Stocks Zacks
Dec-23-19 04:19PM	Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-22-19 05:05AM	3 Healthcare Stocks With 100% Street Support TipRanks
Dec-20-19 08:12AM	The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering Benzinga +5.63%
Dec-19-19 12:50PM	Bed Bath & Beyond and 3 more stocks showing momentum MarketWatch +6.40%
12:05PM	4 Momentum Stocks To Watch Benzinga
07:05AM	Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock GlobeNewswire
Dec-18-19 04:01PM	Axsome Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +10.62%
Dec-17-19 07:56AM	The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga
07:00AM	Axsome Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-16-19 08:43AM	Axsome shares jump on positive findings for depression drug MarketWatch +70.55%
06:00AM	Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder GlobeNewswire
Dec-11-19 11:04PM	Did Hedge Funds Drop The Ball On Axsome Therapeutics, Inc. (AXSM)? Insider Monkey
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga +5.06%
Dec-04-19 10:02AM	Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
08:20AM	Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up Zacks
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 08:56AM	Implied Volatility Surging for Axsome (AXSM) Stock Options Zacks +15.12%
06:00AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy GlobeNewswire
Nov-21-19 07:00AM	Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine GlobeNewswire
Nov-20-19 05:28PM	Edited Transcript of AXSM earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +7.49%
Nov-07-19 07:00AM	Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -9.67%
Oct-29-19 07:00AM	Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire
Oct-28-19 01:23PM	Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey
07:05AM	Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine GlobeNewswire
07:00AM	Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine GlobeNewswire
Oct-21-19 07:00AM	Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy GlobeNewswire
Oct-16-19 07:00AM	Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
05:03AM	Riding 2 Big Winners in Small Biotech TheStreet.com
Oct-03-19 08:41AM	Axsome (AXSM) Catches Eye: Stock Jumps 9.3% Zacks
Oct-02-19 07:00AM	Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference GlobeNewswire +9.28%
Oct-01-19 08:54AM	Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? Zacks -17.44%
05:53AM	CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM) Simply Wall St.
Sep-18-19 02:08PM	Axsome Shares Flirt With Record High: How Much Upside Is Left? Benzinga
Sep-04-19 01:25PM	How Much Are Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Spending On Buying Shares? Simply Wall St.
Sep-03-19 07:00AM	Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-31-19 01:19AM	Edited Transcript of AXSM earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 08:58AM	Is the Options Market Predicting a Spike in Axsome (AXSM) Stock? Zacks
Aug-20-19 07:00AM	Axsome Therapeutics Appoints David Marek as Chief Commercial Officer GlobeNewswire
Aug-09-19 11:52AM	Axsome Therapeutics, Inc. (AXSM) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:00AM	Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-30-19 07:00AM	Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019 GlobeNewswire
Jul-29-19 07:00AM	Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility GlobeNewswire
Jul-16-19 07:46PM	About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
Jul-12-19 08:50AM	Implied Volatility Surging for Axsome (AXSM) Stock Options Zacks

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coleman Mark	Director	Jun 29	Buy	78.50	650	51,025	403,698	Jun 30 08:20 AM
Pizzie Nick	Chief Financial Officer	Jun 29	Buy	76.64	777	59,549	41,217	Jun 30 08:19 AM
JEFFS ROGER	Director	Jan 10	Option Exercise	10.46	60,186	629,756	116,806	Jan 14 04:08 PM
Pizzie Nick	Chief Financial Officer	Sep 26	Buy	24.80	2,180	54,064	40,440	Sep 30 07:16 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience